We are live on ! Find out more

CDT Equity Inc

CDT

Market cap $1.33M

1.31 USD

+0.46

54.85%

At close Updated Nov 6, 4:00 PM EST

Pre-market

After hours

1.20

-0.11

8.4%

1 day

54.85%

5 days

5.65%

1 month

-92.96%

3 months

-99.92%

6 months

-99.99%

Year to date

-100%

1 year

-100%

5 years

-100%

10 years

-100%

About: CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Employees: 4

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 30, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today welcomed a significant development in the U.S. regulatory landscape for compounded peptides, which the Company believes is supportive of its strategic investment in Pep'd Inc., a U.S.-based peptide and telehealth company.

CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides

CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company"), today announced that it has entered into an evaluation agreement with Manoira Corporation ("Manoira"), a specialty animal health company, to assess the potential of CDT's clinical-stage assets AZD1656, including certain proprietary cocrystal derivatives, and AZD5904 to enhance Manoira's forthcoming animal health products.

CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 14, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today notes the announcement from Sarborg Limited regarding intellectual property covering novel solid forms of a major, first-in-class respiratory medicine, an asset class addressing a treatment market estimated at more than $20 billion annually.

CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset

CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

CDT Equity Inc. Announces Reverse Stock Split

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.

CDT Equity Inc. Announces Reverse Stock Split

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo

CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Provides Capital Update and Confirms No Nasdaq Deficiencies

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept.

CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that new solid forms and alternative crystal structures of its existing drug compounds, show enhanced physical property advantages, including improved stability, solubility, manufacturability, over existing forms of these compounds.

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

See News Rankings

Price charts implemented using Lightweight Charts™